Kymera Therapeutics, Inc. Board of Directors

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Dr. Nello Mainolfi M.D., Ph.D.

Dr. Nello Mainolfi M.D., Ph.D.

Co-Founder, President, CEO & Director

Mr. Bruce N. Jacobs CFA

Mr. Bruce N. Jacobs CFA

Chief Financial Officer

Dr. Bruce L. Booth DPHIL, Ph.D.

Dr. Bruce L. Booth DPHIL, Ph.D.

Co-Founder & Independent Chairman

Ms. Ellen V. Chiniara Esq., J.D.

Ms. Ellen V. Chiniara Esq., J.D.

Chief Legal Officer & Corporate Secretary

Ms. Karen Weisbach

Ms. Karen Weisbach

Head of People & Culture

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.